Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
LRRC8C Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
LRRC8C Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of LRRC8C sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
LRRC8D Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
LRRC8D Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of LRRC8D sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
LAPTM4A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
LAPTM4A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of LAPTM4A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
LIMK1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
LIMK1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of LIMK1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
LATS1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
LATS1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of LATS1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
LCK Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
LCK Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of LCK sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
LIMK2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
LIMK2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of LIMK2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KCNN2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KCNN2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNN2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KCNN3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KCNN3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNN3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KSR1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KSR1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KSR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
LACRT Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
LACRT Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of LACRT sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KSR2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KSR2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KSR2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →